Willem J.M. Mulder, Ph.D. is an Associate Professor in the Department of Radiology at Mount Sinai School of Medicine in New York City. Dr. Mulder obtained a M.Sc. in Chemistry at the Utrecht University (the Netherlands) in 2001 and his Ph.D. in Biomedical Engineering from the Eindhoven University of Technology (the Netherlands) in 2006. Thereafter, he was appointed Assistant Professor of Radiology at Mount Sinai’s Translational and Molecular Imaging Institute (TMII) and founded the Nanomedicine Laboratory in October 2006. In July 2012 Dr. Mulder was appointed Associate Professor of Radiology. Dr. Mulder is a renowned investigator in the filed of cardiovascular nanomedicine and the focus of his research is on the development of translational nanomedical approaches towards molecular imaging and targeted therapy of cancer and cardiovascular disease (Nat Rev Drug Discov. 2011;10:835-52; Acc Chem Res. 2009 Jul 21;42(7):904-14). He has authored more than 75 peer-reviewed publications, 10 book chapters, and over 150 meeting presentations. He is currently the Principal Investigator of a National Institutes of Health’s National Cancer Institute R01 grant and serves as a Principal Investigator for one of the projects of a recent large award from the National Heart Lung and Blood Institute Program of Excellence in Nanotechnology (PIs Zahi A. Fayad and Robert Langer). Dr. Mulder trained more than 20 postdocs and students and currently leads a team of 5 postdocs, 2 technicians and 5 (Ph.D.) students.
Multi-Disciplinary Training Area
Pharmacology and Therapeutics Discovery [PTD]Education
MSc, Utrecht University
PhD, Eindhoven University of Technology
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Mulder did not report having any of the following types of financial relationships with industry during 2018 and/or 2019: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.